BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 20823195)

  • 21. Intracerebroventricular passive immunization in transgenic mouse models of Alzheimer's disease.
    Chauhan NB; Siegel GJ
    Expert Rev Vaccines; 2004 Dec; 3(6):717-25. PubMed ID: 15606357
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunotherapy reduces vascular amyloid-beta in PDAPP mice.
    Schroeter S; Khan K; Barbour R; Doan M; Chen M; Guido T; Gill D; Basi G; Schenk D; Seubert P; Games D
    J Neurosci; 2008 Jul; 28(27):6787-93. PubMed ID: 18596154
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Passive immunization of the Abeta42(43) C-terminal-specific antibody BC05 in a mouse model of Alzheimer's disease.
    Asami-Odaka A; Obayashi-Adachi Y; Matsumoto Y; Takahashi H; Fukumoto H; Horiguchi T; Suzuki N; Shoji M
    Neurodegener Dis; 2005; 2(1):36-43. PubMed ID: 16909001
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sustained levels of antibodies against Aβ in amyloid-rich regions of the CNS following intravenous dosing in human APP transgenic mice.
    Bard F; Fox M; Friedrich S; Seubert P; Schenk D; Kinney GG; Yednock T
    Exp Neurol; 2012 Nov; 238(1):38-43. PubMed ID: 22892246
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intramuscular delivery of a single chain antibody gene prevents brain Aβ deposition and cognitive impairment in a mouse model of Alzheimer's disease.
    Wang YJ; Gao CY; Yang M; Liu XH; Sun Y; Pollard A; Dong XY; Wu XB; Zhong JH; Zhou HD; Zhou XF
    Brain Behav Immun; 2010 Nov; 24(8):1281-93. PubMed ID: 20595065
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Imaging brain amyloid of Alzheimer disease in vivo in transgenic mice with an Abeta peptide radiopharmaceutical.
    Lee HJ; Zhang Y; Zhu C; Duff K; Pardridge WM
    J Cereb Blood Flow Metab; 2002 Feb; 22(2):223-31. PubMed ID: 11823720
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modulation of microglial activation state following passive immunization in amyloid depositing transgenic mice.
    Morgan D
    Neurochem Int; 2006 Jul; 49(2):190-4. PubMed ID: 16740342
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Magnetic resonance spectroscopic analysis of Alzheimer's disease mouse brain that express mutant human APP shows altered neurochemical profile.
    Dedeoglu A; Choi JK; Cormier K; Kowall NW; Jenkins BG
    Brain Res; 2004 Jun; 1012(1-2):60-5. PubMed ID: 15158161
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Magnetic resonance imaging of Alzheimer's pathology in the brains of living transgenic mice: a new tool in Alzheimer's disease research.
    Jack CR; Marjanska M; Wengenack TM; Reyes DA; Curran GL; Lin J; Preboske GM; Poduslo JF; Garwood M
    Neuroscientist; 2007 Feb; 13(1):38-48. PubMed ID: 17229974
    [TBL] [Abstract][Full Text] [Related]  

  • 30. APP transgenic mice: the effect of active and passive immunotherapy in cognitive tasks.
    Röskam S; Neff F; Schwarting R; Bacher M; Dodel R
    Neurosci Biobehav Rev; 2010 Mar; 34(4):487-99. PubMed ID: 19857518
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vivo targeting of antibody fragments to the nervous system for Alzheimer's disease immunotherapy and molecular imaging of amyloid plaques.
    Poduslo JF; Ramakrishnan M; Holasek SS; Ramirez-Alvarado M; Kandimalla KK; Gilles EJ; Curran GL; Wengenack TM
    J Neurochem; 2007 Jul; 102(2):420-33. PubMed ID: 17596213
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gantenerumab: a novel human anti-Aβ antibody demonstrates sustained cerebral amyloid-β binding and elicits cell-mediated removal of human amyloid-β.
    Bohrmann B; Baumann K; Benz J; Gerber F; Huber W; Knoflach F; Messer J; Oroszlan K; Rauchenberger R; Richter WF; Rothe C; Urban M; Bardroff M; Winter M; Nordstedt C; Loetscher H
    J Alzheimers Dis; 2012; 28(1):49-69. PubMed ID: 21955818
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genomic analysis of response to traumatic brain injury in a mouse model of Alzheimer's disease (APPsw).
    Crawford FC; Wood M; Ferguson S; Mathura VS; Faza B; Wilson S; Fan T; O'Steen B; Ait-Ghezala G; Hayes R; Mullan MJ
    Brain Res; 2007 Dec; 1185():45-58. PubMed ID: 17961517
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The murine version of BAN2401 (mAb158) selectively reduces amyloid-β protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice.
    Tucker S; Möller C; Tegerstedt K; Lord A; Laudon H; Sjödahl J; Söderberg L; Spens E; Sahlin C; Waara ER; Satlin A; Gellerfors P; Osswald G; Lannfelt L
    J Alzheimers Dis; 2015; 43(2):575-88. PubMed ID: 25096615
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antibody therapy for Alzheimer's disease.
    Morgan D
    Expert Rev Vaccines; 2003 Feb; 2(1):53-9. PubMed ID: 12901597
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dynamics of Abeta turnover and deposition in different beta-amyloid precursor protein transgenic mouse models following gamma-secretase inhibition.
    Abramowski D; Wiederhold KH; Furrer U; Jaton AL; Neuenschwander A; Runser MJ; Danner S; Reichwald J; Ammaturo D; Staab D; Stoeckli M; Rueeger H; Neumann U; Staufenbiel M
    J Pharmacol Exp Ther; 2008 Nov; 327(2):411-24. PubMed ID: 18687920
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer's disease study cohorts from phase 3 trials of semagacestat and solanezumab.
    Carlson C; Estergard W; Oh J; Suhy J; Jack CR; Siemers E; Barakos J
    Alzheimers Dement; 2011 Jul; 7(4):396-401. PubMed ID: 21784350
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanisms of A beta plaque clearance following passive A beta immunization.
    Morgan D
    Neurodegener Dis; 2005; 2(5):261-6. PubMed ID: 16909007
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Longitudinal noninvasive magnetic resonance imaging of brain microhemorrhages in BACE inhibitor-treated APP transgenic mice.
    Beckmann N; Doelemeyer A; Zurbruegg S; Bigot K; Theil D; Frieauff W; Kolly C; Moulin P; Neddermann D; Kreutzer R; Perrot L; Brzak I; Jacobson LH; Staufenbiel M; Neumann U; Shimshek DR
    Neurobiol Aging; 2016 Sep; 45():50-60. PubMed ID: 27459925
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Monoclonal antibodies against β-amyloid (Aβ) for the treatment of Alzheimer's disease: the Aβ target at a crossroads.
    Panza F; Frisardi V; Imbimbo BP; Seripa D; Solfrizzi V; Pilotto A
    Expert Opin Biol Ther; 2011 Jun; 11(6):679-86. PubMed ID: 21501112
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.